Integrated Micro-Chromatography Systems, Inc (IMCS) designs, develops, manufactures, and distributes next-generation recombinant proteins and chromatography consumables to clinical and forensic toxicology laboratories, academic research facilities, US government agencies, and life science companies worldwide. The company has two product lines: IMCSzyme® and IMCStips®.
The industry-disrupting IMCSzyme is a genetically modified enzyme primarily used for the drug screening and analysis of urine and other biological samples. IMCStips are utilize patented dispersive solid-phase extraction (dSPE) technology for purifying new proteins, antibodies, and enzymes, as part of drug discovery from validation to development, screening, and manufacturing.
Recently, IMCS was awarded NIH funds to manufacture various glycosyltransferases to leverage the company’s advanced manufacturing and research capabilities to expand the synthesis of glycosphingolipids and sialoglycans. This expands IMCS product lines and delivers critically needed biological reagents that were previously unavailable to the scientific community.